There is neuropathologic evidence that confluent MRI white matter lesions in the elderly reflect ischemic brain damage due to microangiopathy. The authors hypothesize that measuring changes in the progression of white matter lesions as shown by MRI may provide a surrogate marker in clinical trials on cerebral small-vessel disease in which the currently used primary outcomes are cognitive impairment and dementia. This hypothesis is based on evidence that confluent white matter lesions progress rapidly as shown in a recent follow-up study in community-dwelling subjects. The mean increase in lesion volume was 5.2 cm(3) after 3 years. Based on these data in a clinical trial, 195 subjects with confluent lesions would be required per treatment arm to demonstrate a 20% reduction in the rate of disease progression over a 3-year period. Like any other MRI metric, the change in white matter lesion volume cannot be considered preferable to clinical outcomes unless it has been demonstrated that it matters to the patient in terms of function.

White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease / R. Schmidt, P. Scheltens, T. Erkinjuntti, L. Pantoni, H.S. Markus, A. Wallin, F. Barkhof, F. Fazekas. - In: NEUROLOGY. - ISSN 1526-632X. - 63:1(2004 Jul 13), pp. 139-144.

White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease

L. Pantoni
;
2004

Abstract

There is neuropathologic evidence that confluent MRI white matter lesions in the elderly reflect ischemic brain damage due to microangiopathy. The authors hypothesize that measuring changes in the progression of white matter lesions as shown by MRI may provide a surrogate marker in clinical trials on cerebral small-vessel disease in which the currently used primary outcomes are cognitive impairment and dementia. This hypothesis is based on evidence that confluent white matter lesions progress rapidly as shown in a recent follow-up study in community-dwelling subjects. The mean increase in lesion volume was 5.2 cm(3) after 3 years. Based on these data in a clinical trial, 195 subjects with confluent lesions would be required per treatment arm to demonstrate a 20% reduction in the rate of disease progression over a 3-year period. Like any other MRI metric, the change in white matter lesion volume cannot be considered preferable to clinical outcomes unless it has been demonstrated that it matters to the patient in terms of function.
Austrian stroke prevention; sclerosis treatment trials; multiple-sclerosis; vascular dementia; intracerebral hemorrhage; cognitive impairment; MR-angiography; follow-up; abnormalities; hyperintensities
Settore MED/26 - Neurologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
WML surrogate marker_Schmidt_Neurology 2004.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 221.24 kB
Formato Adobe PDF
221.24 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/579358
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 158
  • ???jsp.display-item.citation.isi??? 141
social impact